The Weekly Litigation News Digest is now live. Subscribe now

Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer - EP3305285

The patent EP3305285 was granted to Aragon Pharmaceuticals on Sep 2, 2020. The application was originally filed on Sep 23, 2013 under application number EP17187458A. The patent is currently recorded with a legal status of "Revoked".

EP3305285

ARAGON PHARMACEUTICALS
Application Number
EP17187458A
Filing Date
Sep 23, 2013
Status
Revoked
Aug 22, 2024
Publication Date
Sep 2, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZJun 2, 2021MAIWALDADMISSIBLE
SYNTHONJun 2, 2021HAMM & WITTKOPPADMISSIBLE
TEVA PHARMACEUTICALSJun 2, 2021D YOUNGADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
OPPOSITIONEP1007080
SEARCHWO2012158884
SEARCHWO2013079964

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents